Clinical

Golimumab approved for treating some forms of UC

On 15 May 2013, the U.S. Food and Drug Administration approved a new use for Simponi (golimumab) injection: treatment of adults with moderate to severe ulcerative colitis that is resistant (refractory) to prior treatment or requires continuous steroid therapy. Golimumab had previously been approved to treat rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (arthritis affecting the joints in the spine and the pelvis). The press release provides full details.